E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 7/9/2021 in the Prospect News Structured Products Daily.

New Issue: HSBC sells $104,000 buffered accelerated market participation notes on biotech ETF

By Kiku Steinfeld

Chicago, July 9 – HSBC USA Inc. priced $104,000 of 0% buffered Accelerated Market Participation Securities due May 28, 2024 linked to the SPDR S&P Biotech ETF, according to a 424B2 filing with the Securities and Exchange Commission.

If the fund return is positive, the payout at maturity will be par plus 150% of the fund return, capped at par plus 23.6%.

Investors will receive par if the fund falls by 15% or less and will lose 1% for every 1% decline beyond the 15% buffer.

HSBC Securities USA Inc. is the agent.

Issuer:HSBC USA Inc.
Issue:Buffered Accelerated Market Participation Securities
Underlying fund:SPDR S&P Biotech ETF
Amount:$104,000
Maturity:May 28, 2024
Coupon:0%
Price:Par
Payout at maturity:If fund return is positive, par plus 150% of fund return, capped at par plus 23.6%; par if fund declines by 15% or less; 1% loss for every 1% fund declines beyond 15% buffer
Initial index level:$125.84
Buffer level:85% of initial level
Pricing date:May 24
Settlement date:May 27
Agent:HSBC Securities (USA) Inc.
Fees:2.5%
Cusip:40438C6Z9

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.